Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Euroz Hartleys 2025 Healthcare Forum
14 slides from Proteomics International Laboratories's conference presentation, Feb 4, 2025
Slide 1: ASX Release: Investor Presentation
ASX Release 4 February 2025 ASX code: PIQ Investor Presentation Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ), a pioneer in precision diagnostics, is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to delegates at Euroz Hartleys 2
Slide 2: Proteomics International Euroz Hartleys 2025 Healthcare Forum
ASX: PIQ Proteomics International LABORATORIES LTD Euroz Hartleys 2025 Healthcare Forum Investor Presentation 4 February 2025 Dr. Richard Lipscombe Managing Director 1
Slide 3: Disclaimer
Disclaimer ASX: PIQ This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in
Slide 4: Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd ASX: PIQ A medical technology company at the forefront of precision diagnostics Commercialising three first-in-class tests driven by a proprietary platform technology: • A novel and accurate test for predicting the onset of chronic kidney disease in type 2 a
Slide 5: Corporate Overview
Corporate Overview ASX: PIQ Financial and Corporate Corporate Snapshot ASX code PIQ • Top 40 Shareholders hold 41% Market Capitalisation A$85m Cash (31 Dec 2024) ~A$5.3m • Directors are highly aligned with shareholders holding 13% Share Price (31 Jan 2025) A$0.645 • State-of-the-art laboratories Sha
Slide 6: The Need: Target Populations for DKD, Endo and Eso
The Need: Target Populations for DKD, Endo and Eso ASX: PIQ 10.5% of the global adult 1 in 9 women have 1-2% of western populations at risk population have diabetes endometriosis of Esophageal Cancer (Diagnosed by endoscopy with biopsy) 537m adults 378m 20-120m adults globally have women in eligible
Slide 7: Go-to-Market: Synergistic pathways
Go-to-Market: Synergistic pathways ASX: PIQ Direct to consumer/patient (DTC/DTP) and digital marketing pathway PI establishes Blood collection engaged and PI receives payment reference laboratory samples run Telehealth consult: Promarker Hub Direct patient & clinician referral Traditional licensing
Slide 8: Go-to-Market
Go-to-Market ASX: PIQ Direct to consumer/patient (DTC/DTP) digital platform • Preparing to launch in Australia in Q1 CY25 ➢ Automated immunoassay established ➢ Clinical accreditation in progress ➢ Blood collection logistics established ➢ GP practices engaged ➢ Beta-testing digital platforms 7
Slide 9: Go-to-Market: Benefits
Go-to-Market: Benefits ASX: PIQ Direct License Establishment and tech transfer risk Low (PI controlled) Medium Time to operations 1H 2025 (Australia and US) To follow Direct market launch High % (75-100% depending on Low % (5-25% increasing with Proteomics retained test fee contractors) market valid
Slide 10: Multiple Value Drivers in H1 CY25
Multiple Value Drivers in H1 CY25 ASX: PIQ Milestone TARGET Qtr Dec Mar Jun Impact Commercial US reference lab established Key to first US sales and reimbursement First Sales PromarkerD in USA Initiate pathway to significant revenues Australian clinical lab certification established PromarkerD launc
Slide 11: Summary – Exceptional Growth Opportunity
ASX: PIQ • Disruptive, cutting-edge technology & proven in-house diagnostics platform Summary – • Multiple patented products Exceptional • PromarkerD test de-risked, patented, revenue ready Growth • PromarkerEndo and PromarkerEso tests nearing market Opportunity entry • Tests are scalable with high
Slide 12: Supplemental
Supplemental 11
Slide 13: Board of Directors
Board of Directors ASX: PIQ Dr James Williams PhD (Melbourne), MBA (UWA), BSc, Hons (Aberdeen), GAICD, Non-Executive Chair Accomplished manager, director, scientist and investor with experience covering all aspects of life-science technology translation. Involved from startup to commercialisation, i
Slide 14: Contact
Contact ASX: PIQ Dr Richard Lipscombe Dirk van Dissel Managing Director Investor Relations T: +61 8 9389 1992 Candour Advisory E: enquiries@proteomicsinternational.com T: +61 408 326 367 www.proteomicsinternational.com E: dirk@candouradvisory.com.au ASX:PIQ 13
Proteomics International Laboratories — Euroz Hartleys 2025 Healthcare Forum on 6ix